Prevention of hemophilic arthropathy and peculiarities of rehabilitation at different stages of its development: 612.115.4

Abstract

Summary. Hemorrhages in large joints are among the most common clinical manifestations of hemophilia. With the development of hemarthrosis, a pathogenetic cascade is launched, which leads to the development of hemophilic arthropathy, to prevent the development of which adequate preventive hemostatic therapy is necessary. One of the main principles of hemophilia patient management is the immediate treatment of bleeding episodes, followed by observation, exercise therapy and rehabilitation. The review discusses the safety of rehabilitation, the use of individual rehabilitation programs, and increasing patient adherence to treatment. For the purpose of preventive hemostatic therapy, allowing patients to lead an active lifestyle, prolonged blood coagu- lation factor VIII — efmoroctocog alpha, which effectiveness has been shown in a number of clinical studies, can be effectively used. The review presents clinical observations of the successful efmoroctocog alfa use in patients with hemophilia and hemarthrosis.

For citation: Zorenko V.Yu., Polyanskaya T.Yu., Sadykova N.V., Karpov E.E. Prevention of hemophilic arthropathy and peculiarities of rehabilitation at different stages of its development. Tromboz, gemostaz i reologiya. 2023;(4):11–18. (In Russ.).

References

1. Rodriguez-Merchan E.C., De la Corte-Rodriguez H. Complications of hemophilia in the elbow: current management. Expert Rev Hematol. 2020;13(9):991–1001. DOI: 10.1080/17474086.2020. 1803061.
2. Rodriguez-Merchan E. C., De la Corte-Rodriguez H. Iliopsoas hematomas in people with hemophilia: diagnosis and treatment. Expert Rev Hematol. 2020;13(8):803–9. DOI: 10.1080/17474086.2 020.1787146.
3. Polyanskaya T.Yu., Zorenko V.Yu., Karpov E.E. Modern concepts of the pathogenesis of haemophilic arthropathy. Voprosy gematologii/ onkologii i immunopatologii v pediatrii. 2015;14(3):5–12. (In Russ.). DOI: 10.24287/1726-1708-2015-14-3-5-12.
4. Pacheco-Serrano A.I., Lucena-Antón D., Moral-Muñoz J.A. Physical rehabilitation of patients with hemophilic arthropathy: Systematic review and pain-related meta-analysis. Rev Colomb Reumatol. 2021;28(2):124–33. DOI: 10.1016/j.rcreue.2020.05.008.
5. Srivastava A., Santagostino E., Dougall A. et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1–158. DOI: 10.1111/hae.14046.
6. Kabaeva E.N., Zmachinsky V.A., Khamko K.M. et al. Comparative assessment of medical rehabilitation effectiveness of the musculoskeletal system in patients with severe hemophilia. Medicinskie novosti. 2014;(4):59–61. (In Russ.).
7. Rodriguez-Merchan E.C. Articular bleeding in hemophilia. Cardiovasc Hematol Disord Drug Targets. 2016;16(1):21–4. DOI: 10.217 4/1871529x16666160613114506.
8. Elshennawy S., Zahreldin A.A., Mortada H. et al. The efficacy of physical therapy modalities in patients with hemophilia: A systematic review of randomized controlled trials with meta-analysis. Arch Phys Med Rehabil. 2023;104(3):475–89. DOI: 10.1016/j. apmr.2022.05.023.
9. Rodriguez-Merchan E.C., De la Corte-Rodriguez H. Pain management in people with hemophilia in childhood and young adulthood. Expert Rev Hematol. 2021;14(6):525–35. DOI: 10.1080/17474 086.2021.1935852.
10. Carlsson K.S., Winding B., Astermark J. et al. High use of pain, depression, and anxiety drugs in hemophilia: > 3000 people with hemophilia in an 11-year Nordic registry study. Res Pract Thromb Haemost. 2023;7(2):100061. DOI: 10.1016/j.rpth.2023.100061.
11. Sun J., Zhou X., Hu N. Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review. Orphanet J Rare Dis. 2021;16:287. DOI: 10.1186/ s13023-021-01919-w.
12. Chen C.M., Huang K.C., Chen C.C. et al. The impact of joint range of motion limitations on health-related quality of life in patients with haemophilia A: a prospective study. Haemophilia. 2015;21(3): e176-e184. DOI: 10.1111/hae.12644.
13. El Hawary M.A., EL Dash H.H., Foaud N.A., Mohamed M.H. Effect of joint range of motion on health-related quality of life in children with hemophilia. Egypt Rheumatol Rehabil. 2019;46(4):237– 43. DOI: 10.4103/err.err_18_19.
14. Ogawa Y., Amano K., Matsuo-Tezuka Y. et al. ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database. Int J Hematol. 2023;117(1):44–55. DOI: 10.1007/ s12185-022-03467-w.
15. Zanon E., Tagliaferri A., Pasca S. et al. Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. Blood Transfus. 2020;18(2):152–8. DOI: 10.2450/2019.0040-19.
16. García-Dasí M., Aznar J.A., Jiménez-Yuste V. et al. Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia. 2015;21(4):458–64. DOI: 10.1111/hae.12618.
17. Frampton J. E. Efmoroctocog alfa: a review in haemophilia A. Drugs. 2021;81(17):2035–46. DOI: 10.1007/s40265-021-01615-w.
18. Mahlangu J., Powell J.S., Ragni M.V. et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317–25. DOI: 10.1182/blood-2013-10-529974.
19. Shrestha A., Su J., Li N. et al. Physical activity and bleeding outcomes among people with severe hemophilia on extended halflife or conventional recombinant factors. Res Pract Thromb Haemost. 2021;5(1):94–103. DOI: 10.1002/rth2.12437.
20. Quon D.V., Klamroth R., Kulkarni R. et al. Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies. Haemophilia. 2017;23(1):e39-e42. DOI: 10.1111/hae.13125.
21. Nolan B., Mahlangu J., Pabinger I. et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020;26(3):494–502. DOI: 10.1111/hae.13953.
22. Wyrwich K.W., Krishnan S., Auguste P. et al. Changes in healthrelated quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016;22(6):866–72. DOI: 10.1111/hae.12987.
23. Pasi J., Hermans C., Hakimi Z. et al. Improvement in painrelated quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study. Ther Adv Hematol. 2022;13(1):20406207221079480. DOI: 10.1177/20406207221079482.
24. Skinner M.W., Nugent D., Wilton P. et al. Achieving the unimaginable: Health equity in haemophilia. Haemophilia. 2020;26(1):17– 24. DOI: 10.1111/hae.13862.
25. Heijnen L., Buzzard B.B. The role of physical therapy and rehabilitation in the management of hemophilia in developing countries. Semin Thromb Hemost. 2005;31(5):513–7. DOI: 10.1055/ s-2005-922222.
26. Hilberg T., Herbsleb M., Puta C. et al. Physical training increases isometric muscular strength and proprioceptive performance in haemophilic subjects. Haemophilia. 2003;9(1):86–93. DOI: 10.1046/j.1365-2516.2003.00679.x.
27. Calatayud J., Pérez-Alenda S., Carrasco J.J. et al. Upper-body exercises with external resistance are well tolerated and enhance muscle activity in people with hemophilia. Phys Ther. 2019;99(4):411–9. DOI: 10.1093/ptj/pzy136.
28. Scaturro D., Benedetti M.G., Lomonaco G. et al. Effectiveness of rehabilitation on pain and function in people affected by hemophilia. Medicine (Baltimore). 2021;100(50):e27863. DOI: 10.1097/ MD.0000000000027863.
29. Sørensen B., Auerswald G., Benson G. et al. Rationale for individualizing haemophilia care. Blood Coagul Fibrinolysis. 2015;26(8):849– 57. DOI: 10.1097/MBC.0000000000000225.
30. Wagner B., Seuser A., Krüger S. et al. Establishing an online physical exercise program for people with hemophilia. Wien Klin Wochenschr. 2019;131(21–22):558–66. DOI: 10.1007/ s00508-019-01548-1.
31. Qian W., Lam T.T.-N., Lam H.H.W. et al. Telehealth Interventions for Improving Self-Management in patients with Hemophilia: scoping review of clinical studies. J Med Internet Res. 2019;21(7): e12340. DOI: 10.2196/12340.
32. Zulfikar B., Koc B., Gumustas I., Zulfikar H. Persons with hemophilia of generation Y and their relatives attitudes and expectations from treatment. Clin Appl Thromb Hemost. 2021;27:10760296211000132. DOI: 10.1177/10760296211000131.
33. Zanon E., Tosetto A., Radossi P. et al. Treatment with efmoroctocog alfa (Elocta®) in hemophilia: a case series. Clinical Management Issues. 2020;14(1):61–9. DOI: 10.7175/cmi.v14i1.1484.
34. Andreeva Т.A., Petrov V.Yu., Konstantinova V.N. et al. Use of Efmoroctocog alfa in children and adolescents: clinical observations. Pediatriya. Zhurnal imeni G.N. Speranskogo. 2022;101(5):144– 9. (In Russ.). DOI: 10.24110/0031-403X-2022-101-5-144-149.
35. Zorenko V.Yu., Polyanskaya T.Yu., Sadykova N.V., Karpov E.E. A clinical case of arthroplasty in a patient with hemophilia under therapy with efmoroctocog alfa. Tromboz, gemostaz i reologiya. 2022;(4):85–92. (In Russ.). DOI: 10.25555/THR.2022.4.1044.
36. Soldatenkov V.E., Soldatenkova O.V., Komissarov K.A. et al. Experience of minor surgical interventions in patients with hemophilia A receiving therapy with efmoroctocog alfa. Vestnik gematologii. 2022;18(2):87–8. (In Russ.).